Serial No.:10/566291 Docket No.: X-15998

Amendments to the Claims

IN THE CLAIMS

Please cancel Claims 4, 8, 9, 32, 45, 46, and 48.

Amendments to the Claims

1. (Original). A compound having a formula I,

$$Z \xrightarrow{A_3} Y \xrightarrow{R^2} A_2 \xrightarrow{(R^3)_r} E_1 \xrightarrow{E_2} A_1 \xrightarrow{Q} Q$$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

A₂ and A₃ are independently: CH₂, O or S;

 E_1 , E_2 , E_3 , E_4 and E_5 are each CH or substituted carbon bearing A_2 and R^3 ; or at least one of E_1 , E_2 , E_3 , E_4 and E_5 is nitrogen and each of others being CH or substituted carbon bearing A_2 and R^3 ;

Q is: $-C(O)OR^6$, or R^{6A} ;

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

Z is: a) aryl;

- b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or

Docket No.: X-15998

d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R⁷;

```
n is: 1, 2, 3, 4, 5 or 6
```

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R¹ and R² are each independently:

hydrogen,

haloalkyl,

C₁-C₆ alkyl,

(CH₂)_nC₃-C₈ cycloalkyl, or

 R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R³ is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

 C_1 - C_6 alkyl,

C₁-C₆ alkoxy or

C₃-C₈ cycloalkyl;

R⁴ and R⁵ are each independently: hydrogen or C₁-C₆ alkyl;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R⁷ is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkoxy,

(CH₂)_nC₃-C₈ cycloalkyl,

 $C(O)R^9$,

 $C(O)OR^9$,

 $C(=NOR^8)R^9$,

 $CR^8(OH)R^9$,

 $C[=C(R^8)_2]R^9$,

OR⁹,

SR⁹ or

 $S(O)_pR^9$;

R⁸ is: hydrogen or C₁-C₆ alkyl; and

R⁹ is: hydrogen,

C₁-C₆ alkyl,

C₃-C₈ cycloalkyl,

aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl.

2. (Previously Presented). The compound of Claim 1, wherein the compound is represented by a compound of formula Π ,

$$Z \xrightarrow{Q} Y \xrightarrow{R^1 \quad R^2 \quad (R^3)_r} A_1 \xrightarrow{Q} A_2 \xrightarrow{R^4 \quad R^5}$$
II

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

 A_2 is: O or S or CH_2 ;

Q is: $-C(O)OR^6$, or R^{6A} ;

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

Z is: a) aryl;

- b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or

Serial No.:10/566291 Docket No.: X-15998

d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R⁷;

```
n is: 1, 2, 3, 4, 5 or 6
p is: 1 or 2;
r is: 1, 2, 3, or 4;
```

R¹ and R² are each independently:

hydrogen, haloalkyl,

C₁-C₆ alkyl,

 $(CH_2)_nC_3$ - C_8 cycloalkyl, or

 R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

```
R<sup>3</sup> is: hydrogen,
nitro,
cyano,
hydroxyl,
halo,
haloalkyl,
haloalkyloxy,
aryloxy,
C<sub>1</sub>-C<sub>6</sub> alkyl,
C<sub>1</sub>-C<sub>6</sub> alkoxy, or
C<sub>3</sub>-C<sub>8</sub> cycloalkyl;
```

 R^4 and R^5 are each independently: hydrogen or C_1 - C_6 alkyl;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R⁷ is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkoxy,

(CH₂)_nC₃-C₈ cycloalkyl,

 $C(O)R^9$,

 $C(O)OR^9$,

 $C(=NOR^8)R^9$,

 $CR^8(OH)R^9$,

 $C[=C(R^8)_2]R^9$,

OR⁹,

SR⁹ or

 $S(O)_pR^9$;

R⁸ is: hydrogen or C₁-C₆ alkyl; and

Docket No.: X-15998

R⁹ is: hydrogen,

C₁-C₆ alkyl,

C₃-C₈ cycloalkyl,

aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl.

3. (Original). The compound of Claim 2, wherein Z is optionally substituted phenyl or naphthyl, furanyl, imidazolyl, indolyl, oxazolyl, isoxazolyl, pyridyl, pyrrolyl, thiazolyl, thiophenyl, benzofuranyl, benzothiophenyl, benzoisoxazolyl, quinolinyl, isoquinolinyl or a structural formula selected from following:

$$\begin{array}{c|c} \hline c \\ \hline T \\ \hline \end{array}$$

$$\begin{array}{c|c} \hline f \\ \hline \end{array}$$

$$\begin{array}{c|c} \hline h \\ \hline \end{array}$$

$$\begin{array}{c|c} \hline T \\ \hline \end{array}$$

$$\begin{array}{c|c} \hline g \\ \hline \end{array}$$

$$\begin{array}{c|c} \hline \hline \end{array}$$

wherein T is:

$$a \ bond, \ -(CH_2)_qO-, \ -O(CH_2)_q^-, \ -C(O)(CH_2)_q^-, \ -(CH_2)_qC(O)-, \ -(CH_2)_qS-, \ -S(CH_2)_q^-, \ S[O]_{p,} \\ -(C_1-C_3 \ alkyl)-, \ -(CH_2)_qC(=CH_2)-, \ -C(=CH_2)(CH_2)_q^-, \ -(CH_2)_qC(=NOH)-, \\ -C(=NOH)(CH_2)_q^-, \ -(CH_2)_qC(=NOCH_3)-, \ -C(=NOCH_3)(CH_2)_q^-, \ -CH(OH)(CH_2)_q^-, \ or \\ -(CH_2)_qCH(OH)-,$$

q is: 0, 1, 2 or 3; and

rings b to l are each optionally substituted with one or more groups independently selected from the group consisting of:

Docket No.: X-15998

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

- 4. (Canceled)
- 5. (Previously Presented). The compound of Claim 2, wherein the compound is represented by structural formula IV,

$$R^1$$
 $COOR^6$
 $COOR^6$
 $COOR^6$
 $COOR^6$
 $COOR^6$
 $COOR^6$
 $COOR^6$
 $COOR^6$
 $COOR^6$
 $COOR^6$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

 A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1 or 2;

 R^1 is: C_1 - C_3 alkyl;

 R^3 is: hydrogen, halo or C_1 - C_6 alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

T is: a bond, -O-, -C(O)-, -S(O) –S(O)₂-, -C(=CH₂)-, -C(=NOH)- or -CH(OH)-; and rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

6. (Previously Presented). The compound of Claim 5, wherein the compound is represented by structural formula V,

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

T is: a bond, -O- or -C(O)-;

R¹ is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, methyl, ethyl, isopropyl, $N(CH_3)_2$, $S(O)_2CH_3$, methoxy and cyclopropyl.

7. (Original). The compound of Claim 6, wherein the compound is represented by a structural formula VI,

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 8. (Canceled)
- 9. (Canceled)
- 10. (Previously Presented). The compound of Claim 2, wherein the compound is represented by structural formula VIII,

$$R^3$$
 R^1
 $COOR^6$
 $COOR^6$
 $COOR^6$

VШ

 A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1 or 2;

 R^1 is: C_1 - C_3 alkyl; and

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

T is: a bond, -O-, -C(O)-, -S(O) $-S(O)_2$ -, $-C(=CH_2)$ -, -C(=NOH)- or -CH(OH)-; and

ring b is optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

11. (Previously Presented). The compound of Claim 10, wherein the compound is represented by structural formula IX,

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

 R^1 is C_1 - C_3 alkyl;

 R^3 is: hydrogen, halo or C_1 - C_4 alkyl;

ring b is optionally substituted with one or more groups independently selected from the group consisting of: hydrogen, halo, haloalkyl, haloalkyloxy and C₁-C₆ alkyl.

12. (Previously Presented). The compound of Claim 11, wherein the compound is represented by structural formula X,

$$CF_3 \xrightarrow{CH_3} COOH$$

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

13. (Previously Presented). The compound of Claim 11, wherein the compound is represented by structural formula XI,

$$H_3C$$
 CH_3
 CH_3
 $COOH$
 XI

14. (Previously Presented). The compound of Claim 2, wherein the compound is represented by structural formula $X\Pi$,

$$\begin{array}{c|c} & & & & R^3 \\ \hline & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

XII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1 or 2;

 R^1 is: C_1 - C_3 alkyl; and

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁴, R⁵, R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

rings k and l are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

15. (Canceled)

16. (Previously Presented). The compound of Claim 2, wherein the compound is represented by structural formula XIII,

XIII

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein m is 1, 2, 3, or 4.

17. (Canceled).

18. (Previously Presented). The compound of Claim 16, wherein the compound is represented by structural formula XV,

$$R^2$$
 $COOH$
 $COOH$

XV

T is: a bond, O or C(O);

R² is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, N(CH₃)₂, S(O)₂CH₃, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

19. (Previously Presented). The compound of Claim 2, wherein the compound is represented by structural formula XVI,

XVI

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein Y is a branched alkyl or C₃-C₆ cycloalkyl.

- 20. (Canceled).
- 21. (Previously Presented). The compound of Claim 19, wherein the compound structural formula XVIII,

$$\begin{array}{c|c} R^3 \\ \hline \\ C \\ \hline \\ C \\ \hline \end{array}$$

XVIII

T is: a bond, O or C(O);

R³ is: methyl or ethyl;

 R^{9a} and R^{9b} are each independently hydrogen, methyl or ethyl, wherein at least one of R^{9a} and R^{9b} being methyl or ethyl;

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, S(O)₂CH₃, N(CH₃)₂, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

- 22. (Canceled).
- 23. (Previously Presented). The compound of Claim 1, wherein the compound is a compound of formula XX,

$$Z \xrightarrow{Q} Y \xrightarrow{R^1 \quad R^2} A_1 \xrightarrow{(R^3)_r} A_1 \xrightarrow{Q} XX$$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

A₁ is: a bond, CH₂, O or S, and wherein A₁ and R⁴ or A₁ and R⁵ together being a 3- to 6-membered carbocyclyl when A₁ is a carbon;

A₂ is: O or S or CH₂;

Q is: $-C(O)OR^6$, or R^{6A} ;

Serial No.:10/566291 Docket No.: X-15998

Y is: a bond, C₁-C₆ alkyl or C₃-C₆ cycloalkyl;

Z is: a) aryl;

- b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- c) bi-aryl, wherein biaryl being defined as aryl substituted with another aryl or aryl substituted with heteroaryl, or
- d) bi-heteroaryl, wherein bi-heteroaryl being defined as heteroaryl substituted with another heteroaryl, or heteroaryl substituted with aryl, and wherein aryl, heteroaryl, bi-aryl and bi-heteroaryl being optionally substituted with one or more groups independently selected from R⁷;

```
n is: 1, 2, 3, 4, 5 or 6
```

p is: 1 or 2;

r is: 1, 2, 3, or 4;

R¹ and R² are each independently:

hydrogen,

haloalkyl,

C₁-C₆ alkyl,

(CH₂)_nC₃-C₈ cycloalkyl, or

 R^1 and R^2 form a 4- to 8-membered nonaromatic carbocyclic ring; and wherein at least one of R^1 and R^2 is alkyl or cycloalkyl, and;

R³ is: hydrogen,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

C₁-C₆ alkyl,

C₁-C₆ alkoxy or

C₃-C₈ cycloalkyl;

R⁴ and R⁵ are each independently: hydrogen or C₁-C₆ alkyl;

R⁶ is: hydrogen, C₁-C₆ alkyl or aminoalkyl;

R^{6A} is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R⁷ is: hydrogen,

oxo,

nitro,

cyano,

hydroxyl,

halo,

haloalkyl,

haloalkyloxy,

aryloxy,

arylalkyl,

aminoalkyl,

C₁-C₆ alkyl,

C₁-C₆ alkoxy,

(CH₂)_nC₃-C₈ cycloalkyl,

 $C(O)R^9$,

Docket No.: X-15998

 $C(O)OR^9$,

 $C(=NOR^8)R^9$,

 $CR^8(OH)R^9$,

 $C[=C(R^8)_2]R^9$,

OR⁹,

SR⁹ or

 $S(O)_pR^9$;

R⁸ is: hydrogen or C₁-C₆ alkyl; and

R⁹ is: hydrogen,

C₁-C₆ alkyl,

C₃-C₈ cycloalkyl,

aryl,

heteroaryl or

heterocyclyl,

wherein alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl being optionally substituted with one or more substituents selected from the group consisting of:

hydrogen, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, oxo, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and C_3 - C_8 cycloalkyl.

- 24. (Canceled).
- 25. (Canceled).
- 26. (Previously Presented). The compound of Claim 23, wherein the compound is a compound of structural formula XXII,

T is: a bond, -O- or -C(O)-;

R¹ is: methyl, ethyl or cyclopropyl;

R³ is: methyl or ethyl; and

rings b and c are each optionally substituted with one or more substituent independently selected from the group consisting of: hydrogen, Cl, Br, CF₃, OCF₃, S(O)₂CH₃, N(CH₃)₂, methyl, ethyl, isopropyl, methoxy and cyclopropyl.

27. (Previously Presented). The compound of Claim 1, wherein the compound is a compound of structural formula XXIII,

$$R^{1}$$
 $COOR^{0}$
 $COOR^{0}$

or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein:

 A_1 and A_2 are respectively:

O and O,

CH₂ and O,

CH₂ and S,

O and S or

S and O;

m is: 1, 2, 3 or 4;

R¹ is: C₁-C₃ alkyl; and

R³ is: hydrogen, halo or C₁-C₆ alkyl;

R⁶ and R⁹ are each independently: hydrogen or C₁-C₆ alkyl;

T is: a bond, -O-, -C(O)-, -S(O) –S(O) $_2$ -, -C(=CH $_2$)-, -C(=NOH)- or -CH(OH)-; and rings b and c are each optionally substituted with one or more groups independently selected from:

hydrogen, oxo, nitro, cyano, hydroxyl, halo, haloalkyl, haloalkyloxy, aryloxy, arylalkyl, aminoalkyl, $S(O)_2R^9$, C_1 - C_6 alkyl, C_1 - C_6 alkoxy and $(CH_2)_nC_3$ - C_8 cycloalkyl.

- 28. (Canceled).
- 29. (Previously Presented). A compound of Claim 1 selected from the group consisting of:

No.	Structure	<u>Name</u>
1	H ₃ C OH OH	3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
2	H ₃ C CH ₃ OOO OOO	{4-[3-(2-Benzoyl-4- ethyl-phenoxy)-butoxy]- 2-methyl-phenoxy}- acetic acid
3	H ₃ C CH ₃ OH	{4-[3-(2-Benzoyl-4- ethyl-phenoxy)-butoxy]- 2-methyl- phenylsulfanyl}-acetic acid

No.	Structure	<u>Name</u>
4	H ₃ C CH ₃ OH	{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
5	H ₃ C CH ₃ O OH	{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid
6	H ₃ C CH ₃	3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
7	H_3C CH_3 O CH_3 O	2-{4-[3-(2-Benzoyl-4- ethyl-phenoxy)-butoxy]- 2-methyl-phenoxy}-2- methyl-propionic acid
8	H ₃ C OH	{4-[3-(2-Benzoyl-4- ethyl-phenoxy)-butoxy]- phenoxy}-acetic acid

Serial No.:10/5	66291
-----------------	-------

No.	Structure	<u>Name</u>
9		3-{4-[3-(2-Benzoyl-4-
		isopropyl-phenoxy)-
	H ₃ C, CH ₃	butoxy]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	ĊH ₃ OH	
10	Chiral	3-{4-[3-(2-Benzoyl-4-
		cyclopropyl-phenoxy)-
	CH₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	ČH ₃ OH	
11		3-{4-[3-(2-Benzoyl-4-
		trifluoromethyl-
	F, CH3	phenoxy)-butoxy]-2-
	F O O	methyl-phenyl}-
	CH ₃ OH	propionic acid
12		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	CH ₃	butoxy]-2-methyl-
	CI—O	phenyl}-propionic acid
	ĊH ₃ ОН	
13		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	CH₃	butoxy]-2-methyl-
	CI—CH ₃	phenyl}-propionic acid
	ЮН	

Serial.	N_{Ω}	·10	1566	5201
ъъни	13(1)	- 11.77	ווווי	1/91

No.	Structure	<u>Name</u>
14	Chiral	3-{4-[3-(2-Benzoyl-4-
		methoxy-phenoxy)-
	CH3	butoxy]-2-methyl-
	н ₃ с-о-	phenyl}-propionic acid
	Ċн ₃ У Он	
15	Chiral	3-{4-[3-(2-Benzoyl-4-
		fluoro-phenoxy)-
	CH ₃	butoxy]-2-methyl-
	F—0 — CI 1/3	phenyl}-propionic acid
	LH3	
	ОН	
16	Chiral	3-{4-[3-(2-Benzoyl-4-
		isopropyl-phenoxy)-
	H ₃ C, CH ₃	butoxy]-2-methyl-
	H ₃ C ,0	phenyl}-propionic acid
	ČH₃	
17		{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	> 0	butoxy]-2-methyl-
	CI CH ₃	phenylsulfanyl}-acetic
	CH ₃ OH	acid
18	3	3-(4-{3-[4-Ethyl-2-
10		(hydroxy-phenyl-
)—он	methyl)-phenoxy]-
	H ₃ C CH ₃	butoxy}-2-methyl-
		phenyl)-propionic acid
	ĊH₃	promisi proprome were

No.	Structure	<u>Name</u>
19		3-(4-{3-[4-Ethyl-2-
		(hydroxyimino-phenyl-
	H ₃ C, CH ₃	methyl)-phenoxy]-
		butoxy}-2-methyl-
	CH ₃	phenyl)-propionic acid
20		3-(4-{3-[4-Ethyl-2-
		(methoxyimino-phenyl-
	H ₃ C CH ₃	methyl)-phenoxy]-
		butoxy}-2-methyl-
	CH3 OH	phenyl)-propionic acid
21	H ₃ C CH ₃ Chiral	3-{4-[3-(4-Isopropyl-2-
	H ₃ C O	phenoxy-phenoxy)-
	, o cH³ OH	butoxy]-2-methyl-
		phenyl}-propionic acid
22	Chiral	{4-[3-(4-Isopropyl-2-
		phenoxy-phenoxy)-
	H³C CH³	butoxy]-2-methyl-
	H ₃ C	phenylsulfanyl}-acetic
	H₃C OH	acid
23	H₃C CH₃	3-{4-[3-(4-Ethyl-2-
		isobutyryl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	ĊН ₃ У ОН	
24	\triangleleft	3-{4-[3-(2-
)	Cyclopropanecarbonyl-4-
	H ₃ C CH ₃	ethyl-phenoxy)-butoxy]-
		2-methyl-phenyl}-
	CH ₃ OH	propionic acid

Serial	No	.10	156	6291
Soliai	INU.	1	/ -) (ハノムフェ

No.	Structure	Name
25	\triangleleft	3-{4-[3-(2-
	> 0	Cyclopropanecarbonyl-4-
	H ₃ C CH ₃	ethyl-phenoxy)-butoxy]-
		2-methyl-phenyl}-
	Сн ₃ Он	propionic acid
26		3-{4-[3-(2-
		Cyclopentanecarbonyl-4-
	H ₃ C, CH ₃	ethyl-phenoxy)-butoxy]-
	H ₃ C CH ₃	2-methyl-phenyl}-
	H ₃ C	propionic acid
	`он	
27	H ₃ C CH ₃	2-{4-[3-(4-Ethyl-2-
		isobutyryl-phenoxy)-
	H ₃ C O O O O O O O O O O O O O O O O O O O	butoxy]-phenoxy}-2-
	CH ₃ H ₃ C CH ₃	methyl-propionic acid
28	<	2-{4-[3-(2-
) _0	Cyclopropanecarbonyl-4-
	H ₃ C	ethyl-phenoxy)-butoxy]-
		phenoxy}-2-methyl-
	ĊH ₃ H ₃ C CH ₃ OH	propionic acid
29	H ₃ C CH ₃	3-{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
	OH OH	butoxy]-2-methyl-
		phenyl}-propionic acid
30	/ - \	{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
)—o	butoxy]-2-methyl-
	H ₃ C CH ₃	phenylsulfanyl}-acetic
	CH ₃ OH	acid

No.	Structure	<u>Name</u>
31	Chiral	3-{4-[3-(3-Benzoyl-5-
		chloro-pyridin-2-yloxy)-
	,CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	С̄Н₃	
32	Chiral	{4-[3-(3-Benzoyl-5-
		chloro-pyridin-2-yloxy)-
	CH₃	butoxy]-2-methyl-
		phenylsulfanyl}-acetic
	ČH ₃ OH	acid
33	Chiral	3-{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-
	CH ₃	2-yloxy)-butoxy]-2-
		methyl-phenyl}-
	CH3 OH	propionic acid
34	Chiral	{4-[3-(3-Benzoyl-5-
		trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-2-
	F CH ₃	methyl-phenylsulfanyl}-
	H_3C OH SOH	acetic acid
35	Chiral	3-{4-[3-(5-Chloro-3-
	_ \`	phenoxy-pyridin-2-
	\ ⁶	yloxy)-butoxy]-2-
	CI—CH ₃	methyl-phenyl}-
		propionic acid
	ОН	

No.	Structure	<u>Name</u>
36	Chiral	3-{4-[3-(5-Chloro-3-
		phenoxy-pyridin-2-
	CH ₃	yloxy)-butoxy]-2-ethyl-
		phenyl}-propionic acid
	CH ₃	
37	Chiral	{4-[3-(5-Chloro-3-
		phenoxy-pyridin-2-
		yloxy)-butoxy]-2-
	CI—O—O—S—	methyl-phenylsulfanyl}-
	N H₃C OH	acetic acid
38	F CH ₃ Chiral	3-{2-Methyl-4-[3-(3-
	F F	phenoxy-5-
	O CH ₃	trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-
	-	phenyl}-propionic acid
39	Chiral	3-{2-Ethyl-4-[3-(3-
	>	phenoxy-5-
	F.	trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-
	H ₃ C OH	phenyl}-propionic acid
40	Chiral	3-{2-Ethyl-4-[3-(3-
		phenoxy-5-
	F ∕= CH₃	trifluoromethyl-pyridin-
	F S O	2-yloxy)-butoxy]-
	F —N H ₃ c OH	phenyl}-propionic acid

No.	Structure	<u>Name</u>
41	F OH CH ₃	3-{2-Methyl-4-[3-(3-phenoxy-5-trifluoromethyl-pyridin-2-yloxy)-propoxy]-phenyl}-propionic acid (trifluoroacetic acid salt)
42	F OH CI CH ₃	3-{4-[3-(5-Chloro-3-phenoxy-pyridin-2-yloxy)-propoxy]-2-methyl-phenyl}-propionic acid
43	CI—NOH	3-{4-[2-(5-Chloro-3-phenoxy-pyridin-2-ylamino)-ethoxy]-2-methyl-phenyl}-propionic acid
44	H ₃ C CH ₃	3-{4-[3-(3-Benzoyl-5- ethyl-pyridin-2-yloxy)- propoxy]-2-methyl- phenyl}-propionic acid
45	Chiral H ₃ C OH	3-{2-Methyl-4-[3-(6-methyl-2-phenoxy-pyridin-3-yloxy)-butoxy]-phenyl}-propionic acid

Serial	No.	:10	$\frac{1}{56}$	629	1

No.	Structure	<u>Name</u>
46		3-{4-[3-(5-Ethyl-
		biphenyl-2-yloxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	С́Н₃	
47	Chiral	3-{4-[3-(4-Ethyl-2-
	, cн³	oxazol-2-yl-phenoxy)-
	H ₃ C OH	butoxy]-2-methyl-
	CH ₃	phenyl}-propionic acid
	J	
48	H ₃ C CH ₃ Chiral	3-{4-[3-(4-Ethyl-2-
		thiazol-4-yl-phenoxy)-
	N CH ₃	butoxy]-2-methyl-
	S'	phenyl}-propionic acid
49	Chiral	3-{4-[3-(4-Ethyl-2-
	N N	pyridin-2-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C OH	phenyl}-propionic acid
50	Chiral	{4-[3-(4-Ethyl-2-pyridin-
	N CH3 O	2-yl-phenoxy)-butoxy]-
	H ₃ C OH	2-methyl-
		phenylsulfanyl}-acetic
	H₃C	acid
51	ÇH ₃ Chiral	3-{2-Ethyl-4-[3-(4-ethyl-
	OH	2-pyridin-2-yl-phenoxy)-
		butoxy]-phenyl}-
	CH ₃	propionic acid

Serial	No	.10	156	6291
Soliai	INU.	1	/ -) (ハノムフェ

No.	Structure	<u>Name</u>
52	Chiral	3-{4-[3-(4-Chloro-2-
	>=N	pyridin-2-yl-phenoxy)-
	CI—CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	H₃Ĉ	
53	_ F Chiral	3-{2-Methyl-4-[3-(2-
	F OH	pyridin-2-yl-4-
		trifluoromethyl-
	CH ₃	phenoxy)-butoxy]-
	5113	phenyl}-propionic acid
54	H ₃ C Chiral	3-{2-Ethyl-4-[3-(2-
	F OH	pyridin-2-yl-4-
		trifluoromethyl-
		phenoxy)-butoxy]-
	CH ₃	phenyl}-propionic acid
55	Chiral	3-{4-[3-(4-Ethyl-2-
) N	pyridin-3-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C O	phenyl}-propionic acid
	ОН	
56	Chiral	3-{4-[3-(4-Chloro-2-
	ÇH₃	pyridin-3-yl-phenoxy)-
		butoxy]-2-methyl-
	CH ₃ OH	phenyl}-propionic acid
57	Chiral	3-{4-[3-(4-Ethyl-2-
		pyridin-4-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	ОН	

No.	Structure	<u>Name</u>
58	_ F N CH ₃ O Chiral	3-{2-Methyl-4-[3-(2-
	F OH	pyridin-4-yl-4-
		trifluoromethyl-
		phenoxy)-butoxy]-
	ĈH₃	phenyl}-propionic acid
59	F N H ₃ C Chiral	3-{2-Ethyl-4-[3-(2-
	F OH	pyridin-4-yl-4-
		trifluoromethyl-
		phenoxy)-butoxy]-
	СН ₃	phenyl}-propionic acid
60	N ^O CH₃ O Chiral	3-{4-[3-(2-
	СІ	Benzo[d]isoxazol-3-yl-4-
		chloro-phenoxy)-
		butoxy]-2-methyl-
	ŌH₃	phenyl}-propionic acid
61		3-{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
	CH ₃	2-methyl-phenyl}-
	H ₃ C O	propionic acid
	H ₃ C OH	
62		{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
) =о ,сн₃	2-methyl-phenoxy}-
	H ₃ C	acetic acid
	CH ₃	
63	53	{4-[3-(2-Benzoyl-4-
		ethyl-phenoxy)-butoxy]-
		2-methyl-
	H ₃ C, CH ₃	phenylsulfanyl}-acetic
	s distribution of the state of	acid
	CH ₃	aciu
		1

No.	Structure	<u>Name</u>
64	H ₃ C CH ₃ OCH ₃ OCH	{4-[3-(2-Benzoyl-4- ethyl-phenoxy)-butoxy]- 2-methyl- phenylsulfanyl}-acetic acid
65	H ₃ C S CH ₃ O OH	{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid
66	H ₃ C CH ₃ O OH	3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
67	H_3C CH_3 O CH_3 O	2-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
68	H ₃ C O O O O O O O O O O O O O O O O O O O	{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenoxy}-acetic acid

Serial	No.	.10	156	6291
SULIA	I INU.	1	/ .) ()	ハノムフェ

No.	Structure	<u>Name</u>
69		3-{4-[3-(2-Benzoyl-4-
		isopropyl-phenoxy)-
	H,C ,CH₃	butoxy]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	ĊH ₃ OH	
70	Chiral	3-{4-[3-(2-Benzoyl-4-
		cyclopropyl-phenoxy)-
	, CH³	butoxy]-2-methyl-
		phenyl}-propionic acid
	CH ₃	
71		3-{4-[3-(2-Benzoyl-4-
		trifluoromethyl-
	0	phenoxy)-butoxy]-2-
	F CH ₃	methyl-phenyl}-
	F CH ₃	propionic acid
	ОН	
72		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	CH₃	butoxy]-2-methyl-
	CI—CI—O	phenyl}-propionic acid
	CH₃ OH	
73		3-{4-[3-(2-Benzoyl-4-
		chloro-phenoxy)-
	CH ₃	butoxy]-2-methyl-
	CI—CH ₃	phenyl}-propionic acid
	ОН	

No.	Structure	<u>Name</u>
74	Chiral H ₃ C-O CH ₃ OH	3-{4-[3-(2-Benzoyl-4-methoxy-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
75	Chiral CH ₃ OH	3-{4-[3-(2-Benzoyl-4-fluoro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
76	Chiral H ₃ C H ₃ C CH ₃ OH	3-{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
77	H ₃ C CH ₃ OH	{4-[3-(2-Benzoyl-4-isopropyl-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-aceticacid
78	CI CH ₃ O OH	{4-[3-(2-Benzoyl-4-chloro-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid

Serial	Nο	.10	/56	6291
Dulai	- N V 7 -	1	/ - / \ /	1127

No.	Structure	<u>Name</u>
79		3-(4-{3-[4-Ethyl-2-
		(hydroxy-phenyl-
	H.C. ✓—OH	methyl)-phenoxy]-
	H ₃ C ON 3	butoxy}-2-methyl-
	CH ₃ OH	phenyl)-propionic acid
80	<u>/</u>	3-(4-{3-[4-Ethyl-2-
		(hydroxyimino-phenyl-
	N-OH CH ₃	methyl)-phenoxy]-
	H ₃ C O	butoxy}-2-methyl-
	CH ₃ OH	phenyl)-propionic acid
81		3-(4-{3-[4-Ethyl-2-
		(methoxyimino-phenyl-
	H³C	methyl)-phenoxy]-
		butoxy}-2-methyl-
	ĊH ₃ ОН	phenyl)-propionic acid
82	H ₃ C CH ₃ Chiral	3-{4-[3-(4-Isopropyl-2-
	H ₃ C O	phenoxy-phenoxy)-
	O CH3 OH	butoxy]-2-methyl-
		phenyl}-propionic acid
83	Chiral	{4-[3-(4-Isopropyl-2-
0.5		phenoxy-phenoxy)-
		butoxy]-2-methyl-
	H ₃ C CH ₃	phenylsulfanyl}-acetic
	H ₃ C	acid
	ОН	uoiu
84	H ₃ C CH ₃	3-{4-[3-(4-Ethyl-2-
		isobutyryl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	ĊH₃	

No.	Structure	<u>Name</u>
85	H ₃ C CH ₃ OH	3-{4-[3-(2- Cyclopropanecarbonyl-4- ethyl-phenoxy)-butoxy]- 2-methyl-phenyl}- propionic acid
86	H ₃ C CH ₃ OH	3-{4-[3-(2- Cyclopropanecarbonyl-4- ethyl-phenoxy)-butoxy]- 2-methyl-phenyl}- propionic acid
87	H ₃ C CH ₃	3-{4-[3-(2- Cyclopentanecarbonyl-4- ethyl-phenoxy)-butoxy]- 2-methyl-phenyl}- propionic acid
88	H ₃ C CH ₃ O O O O O O O O O O O O O O O O O O O	2-{4-[3-(4-Ethyl-2-isobutyryl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
89	H ₃ C OH ₃ OH	2-{4-[3-(2- Cyclopropanecarbonyl-4- ethyl-phenoxy)-butoxy]- phenoxy}-2-methyl- propionic acid
90	H ₃ C CH ₃ O CH ₃	3-{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid

No.	Structure	Name
91	H ₃ C CH ₃ OH	{4-[3-(3-Benzoyl-5-ethyl-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
92	Chiral Chiral CH ₃ OH	3-{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
93	CI————————————————————————————————————	{4-[3-(3-Benzoyl-5-chloro-pyridin-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
94	Chiral Chiral CH ₃ OH	3-{4-[3-(3-Benzoyl-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]-2- methyl-phenyl}- propionic acid
95	Chiral Chiral CH ₃ OH	{4-[3-(3-Benzoyl-5- trifluoromethyl-pyridin- 2-yloxy)-butoxy]-2- methyl-phenylsulfanyl}- acetic acid

Serial	No	.10	156	6291
Soliai	INU.	1	/ -) (ハノムフェ

No.	Structure	<u>Name</u>
96	Chiral	3-{4-[3-(5-Chloro-3-
	>	phenoxy-pyridin-2-
	CH ₃	yloxy)-butoxy]-2-
		methyl-phenyl}-
	CH ₃ OH	propionic acid
97	Chiral	3-{4-[3-(5-Chloro-3-
	>	phenoxy-pyridin-2-
	CH₃	yloxy)-butoxy]-2-ethyl-
	CI—CH ₃	phenyl}-propionic acid
	ОН	
98	Chiral	{4-[3-(5-Chloro-3-
	>	phenoxy-pyridin-2-
	CH ₃	yloxy)-butoxy]-2-
		methyl-phenylsulfanyl}-
	—N H₃C OH	acetic acid
99	F CH ₃ Chiral	3-{2-Methyl-4-[3-(3-
		phenoxy-5-
	O CH ₃ OH	trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-
		phenyl}-propionic acid
100	Chiral	3-{2-Ethyl-4-[3-(3-
	<u> </u>	phenoxy-5-
	F, CH ₃	trifluoromethyl-pyridin-
		2-yloxy)-butoxy]-
	H ₃ C OH	phenyl}-propionic acid
101	Chiral	3-{2-Ethyl-4-[3-(3-
		phenoxy-5-
	F, CH ₃	trifluoromethyl-pyridin-
	F N H C O S	2-yloxy)-butoxy]-
	F —N H ₃ C OH	phenyl}-propionic acid

		T
No.	Structure	<u>Name</u>
102	F O	3-{2-Methyl-4-[3-(3-
	, Ł, JOH	phenoxy-5-
	F, CH ₃	trifluoromethyl-pyridin-
	F N O O	2-yloxy)-propoxy]-
	OH	phenyl}-propionic acid
		(trifluoroacetic acid salt)
103	F LO	3-{4-[3-(5-Chloro-3-
	F OH	phenoxy-pyridin-2-
		yloxy)-propoxy]-2-
	o´ ,CH₃	methyl-phenyl}-
	CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-CI-C	propionic acid
	ОН	
104		3-{4-[2-(5-Chloro-3-
		phenoxy-pyridin-2-
	CH₃	ylamino)-ethoxy]-2-
	CI—N	methyl-phenyl}-
		propionic acid
	он	
105	H ₃ C CH ₃	3-{4-[3-(3-Benzoyl-5-
		ethyl-pyridin-2-yloxy)-
	ОН	propoxy]-2-methyl-
		phenyl}-propionic acid
106	Chiral	3-{2-Methyl-4-[3-(6-
		methyl-2-phenoxy-
	N=CH ₃	pyridin-3-yloxy)-
	H ₃ C O	butoxy]-phenyl}-
	H ₃ c OH	propionic acid
107		3-{4-[3-(5-Ethyl-
		biphenyl-2-yloxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	ČH₃	

Serial No.:10/566291

Serial	Nο	·10	156	620
Scriai	INO.	117	/.)U	いとフ

No.	Structure	<u>Name</u>
108	Chiral	3-{4-[3-(4-Ethyl-2-
	, cH³	oxazol-2-yl-phenoxy)-
	H ₃ C OH	butoxy]-2-methyl-
	CH ₃	phenyl}-propionic acid
109	H ₃ C CH ₃ Chiral	3-{4-[3-(4-Ethyl-2-
		thiazol-4-yl-phenoxy)-
	N ČH ₃ OH	butoxy]-2-methyl-
	-5	phenyl}-propionic acid
110	Chiral	3-{4-[3-(4-Ethyl-2-
	N	pyridin-2-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C OH	phenyl}-propionic acid
111	Chiral	{4-[3-(4-Ethyl-2-pyridin-
	, ÇH³ Ů	2-yl-phenoxy)-butoxy]-
	H ₃ C OH	2-methyl-
		phenylsulfanyl}-acetic
	H₃Ĉ	acid
112	CH ₃ Chiral	3-{2-Ethyl-4-[3-(4-ethyl-
	OH	2-pyridin-2-yl-phenoxy)-
		butoxy]-phenyl}-
	CH ₃	propionic acid
113	Chiral	3-{4-[3-(4-Chloro-2-
		pyridin-2-yl-phenoxy)-
	CI—O	butoxy]-2-methyl-
	H ₃ C C	phenyl}-propionic acid
	ОН	
114	ÇH ₃ O Chiral	3-{2-Methyl-4-[3-(2-
	F OH	pyridin-2-yl-4-
		trifluoromethyl-
	$\Gamma_{ ext{CH}_3}$	phenoxy)-butoxy]-

Serial	No.:	10/5	566291
--------	------	------	--------

No.	Structure	<u>Name</u>
		phenyl}-propionic acid
115	F H ₃ C Chiral	3-{2-Ethyl-4-[3-(2-
	F	pyridin-2-yl-4-
		trifluoromethyl-
	CH ₃	phenoxy)-butoxy]-
		phenyl}-propionic acid
116	Chiral	3-{4-[3-(4-Ethyl-2-
	H ₃ C, CH.	pyridin-3-yl-phenoxy)-
	H ₃ C CH ₃	butoxy]-2-methyl-
	H ₃ C OH	phenyl}-propionic acid
117	Chiral	3-{4-[3-(4-Chloro-2-
117	CH ₃	pyridin-3-yl-phenoxy)-
		butoxy]-2-methyl-
		phenyl}-propionic acid
110	ČH ₃ OH	
118	N Chiral	3-{4-[3-(4-Ethyl-2-
	H ₃ C CH ₃	pyridin-4-yl-phenoxy)-
		butoxy]-2-methyl-
	H ₃ C	phenyl}-propionic acid
	'ОН	
119	F CH ₃ O Chiral	3-{2-Methyl-4-[3-(2-
	Б С С С С С С С С С С С С С С С С С С С	pyridin-4-yl-4-
		trifluoromethyl-
	CH ₃	phenoxy)-butoxy]-
		phenyl}-propionic acid
120	F H ₃ C Chiral	3-{2-Ethyl-4-[3-(2-
	F OH	pyridin-4-yl-4-
		trifluoromethyl-
	Å CH₃	phenoxy)-butoxy]-
		phenyl}-propionic acid

No.	Structure	Name
121	N Chiral	3-{4-[3-(2-
	СІ	Benzo[d]isoxazol-3-yl-4-
		chloro-phenoxy)-
		butoxy]-2-methyl-
	С́Н₃	phenyl}-propionic acid
122	Chiral	(R)-{4-[3-(4-ethyl-2-
		phenoxy-phenoxy)-
	H ₃ C, /=\(\)	butoxy]-2-methyl-
		phenylsulfanyl}-acetic
	CH ₃ OH	acid
123	Chiral	(R)-{4-[3-(2-benzoyl-4-
		methyl-phenoxy)-
	CH ₃	butoxy]-2-methyl-
	$H_3C \longrightarrow O \longrightarrow O \longrightarrow S$	phenylsulfanyl}-acetic
	CH ₃ OH	acid
124	Chiral	(R)-{4-[3-(2-benzoyl-4-
		trifluoromethoxy-
	F CH ₃	phenoxy)-butoxy]-2-
	F O - S_O	methyl-phenylsulfanyl}-
	ČH ₃ OH	acetic acid
125		{4-[3-(2-benzoyl-4-ethyl-
		phenoxy)-hexyloxy]-2-
	CH ₃	methyl-phenylsulfanyl}-
	H ₃ C	acetic acid
	ОН	
	L CH ₃	

No.	Structure	Name
126		3-{4-[3-(2-benzoyl-4-
		ethyl-phenoxy)-
	H.C. CH ₃	hexyloxy]-2-methyl-
	H ₃ C O	phenyl}-propionic acid
	ОН	
	СН ₃	
127	Chiral	(R)-3-{4-[3-(4-ethyl-2-
		phenoxy-phenoxy)-
	O CH₃ H₃C, ✓=⟨	butoxy]-2-methyl-
		phenyl}-propionic acid
	CH₃ OH	
128	Chiral	(R)-3-(4-{3-[4-ethyl-2-
		(1-phenyl-vinyl)-
	H_3C CH_2 CH_3	phenoxy]-butoxy}-2-
		methyl-phenyl)-
	CH ₃ OH	propionic acid
129	Chiral	(R)-3-(4-{3-[4-ethyl-2-
	CII	(1-methyl-1-phenyl-
	H ₃ C, CH ₃ CH ₃	ethyl)-phenoxy]-
		butoxy}-2-methyl-
	CH ₃ OH	phenyl)-propionic acid
130	Chiral	(R)-3-{4-[3-(2-benzoyl-
		4-methyl-phenoxy)-
)⇒o ,CH₃	butoxy]-2-methyl-
	H ₃ C-_O_O	phenyl}-propionic acid
	CH ₃ OH	

Serial	No	.10	156	6291
Soliai	INU.	1	/ -) (ハノムフェ

No.	Structure	Name
131	Chiral	(R)-3-(4-{3-[4-ethyl-2-
		(1-phenyl-ethyl)-
	CH ₃	phenoxy]-butoxy}-2-
	H ₃ C O O	methyl-phenyl)-
	CH ₃ OH	propionic acid
132	Chiral	(R)-3-(4-{3-[4-ethyl-2-
	₩ N	(pyridine-2-carbonyl)-
	> O CH₃	phenoxy]-butoxy}-2-
	H ₃ C O O	methyl-phenyl)-
	CH ₃ OH	propionic acid
133		3-(2-methyl-4-{3-[2-
		(thiophene-2-carbonyl)-
	F >= 0 CH ₃	4-trifluoromethoxy-
	f o - o - o - o - o - o - o - o - o - o	phenoxy]-butoxy}-
	ĊH ₃ ОН	phenyl)-propionic acid
134		3-(4-{3-[4-ethyl-2-
	¥*	(thiophene-2-carbonyl)-
	CH ₃	phenoxy]-butoxy}-2-
	H ₃ C 0 0 0	methyl-phenyl)-
	CH ₃ OH	propionic acid
135		3-(4-{3-[4-ethyl-2-
		(naphthalene-1-
)=o ,ch₃	carbonyl)-phenoxy]-
	H ₃ C O	butoxy}-2-methyl-
	CH ₃ OH	phenyl)-propionic acid
136		3-(4-{3-[4-ethyl-2-(1-
		phenyl-vinyl)-phenoxy]-
	CH ₂ CH ₃	butoxy}-2-methyl-
	H ₃ C 0 0 0	phenyl)-propionic acid
	CH₃ OH	

Serial	No.	.10	156	6291
SULIA	I INU.	1	/ .) ()	ハノムフェ

No.	Structure	<u>Name</u>
137	CH ₃ O O OH	3-{4-[3-(2-benzoyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
138	H_3 C CH_3 O CH_3 O O O	3-{4-[3-(2-benzoyl-4-methyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
139	H_3C CH_3 OH	3-{4-[3-(2-benzyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
140	$\begin{array}{c} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$	3-{4-[3-(2-benzoyl-4-bromo-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
141	H ₃ C CH ₃ O CH ₃ O O O O O O O O O O O O O O O O O O O	3-{4-[3-(2-benzoyl-4-butyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid

Serial	No	.10	156	6291
Soliai	INU.	1	/ -) (ハノムフェ

No.	Structure	Name
142		3-{4-[3-(2-benzoyl-4-
		propyl-phenoxy)-
	H ₃ C — CH ₃	butoxy]-2-methyl-
		phenyl}-propionic acid
	CH ₃ OH	
143		3-{4-[4-(2-benzoyl-4-
	ÇH₃ Q	ethyl-phenoxy)-1-
	ÇH₃ CH₃ OH	methyl-butoxy]-2-
		methyl-phenyl}-
	H ₃ C	propionic acid
144		3-{4-[4-(2-benzoyl-4-
	ÇH₃ Q	ethyl-phenoxy)-
	OH OH	pentyloxy]-2-methyl-
		phenyl}-propionic acid
	H ₃ C CH ₃	
145		3-{4-[3-(2-benzoyl-4-
		ethyl-phenoxy)-2-
	H.C. CH ₃ CH ₃	methyl-propoxy]-2-
	H_3C O O O	methyl-phenyl}-
	ОН	propionic acid
146		3-{4-[3-(2-benzoyl-4-
		ethyl-phenoxy)-
	CH ₃	propoxy]-2-methyl-
	H ₃ C O O O	phenyl}-propionic acid
	ОН	
147	F	3-(4-{3-[4-ethyl-2-(4-
		fluoro-benzoyl)-
		phenoxy]-propoxy}-2-
	H ₃ C CH ₃	methyl-phenyl)-
		propionic acid
	ОН	
		1

No.	Structure	<u>Name</u>
148	F F F CH ₃ O OH	3-(4-{3-[4-ethyl-2-(2-trifluoromethyl-benzoyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
149	H ₃ C CH ₃ OH	3-(4-{3-[4-ethyl-2-(3-trifluoromethyl-benzoyl)-phenoxy]-propoxy}-2-methyl-phenyl)-propionic acid
150	H ₃ C CH ₃ OH	3-(4-{3-[4-ethyl-2- (thiophene-2-carbonyl)- phenoxy]-propoxy}-2- methyl-phenyl)- propionic acid
151	H ₃ C CH ₃ O	3-{4-[3-(2-benzyl-4-ethyl-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid
152	H ₃ C CH ₃ OH	3-(4-{3-[4-ethyl-2- (naphthalene-1- carbonyl)-phenoxy]- propoxy}-2-methyl- phenyl)-propionic acid

a · 1	3 T	10	1	((0)1
Serial	NA	. 111	/ > /	56 JUL
OCHA	INU.		/ 23	ハノムフェ

No.	Structure	<u>Name</u>
153		3-(4-{3-[4-ethyl-2-(1-
		phenyl-vinyl)-phenoxy]-
	CH ₂ CH ₃	propoxy}-2-methyl-
	H ₃ C O O O	phenyl)-propionic acid
	ОН	
154		2-{4-[3-(2-benzoyl-4-
		ethyl-phenoxy)-butoxy]-
		phenoxy}-2-methyl-
	H ₃ C O	propionic acid
	H ₃ Ć	
	H ₃ C H ₃ C	
	HÖ	
155		2-{4-[3-(2-benzoyl-4-
		ethyl-phenoxy)-2-
	HC CH ₃	methyl-propoxy]-
	H ₃ C O	phenoxy}-2-methyl-
		propionic acid
	H_3C H_3C	
	но	
156		2-{4-[3-(2-benzyl-4-
		ethyl-phenoxy)-butoxy]-
		phenoxy}-2-methyl-
	H ₃ C O	propionic acid
	H ₃ C	
	H ₃ C H ₃ C	
	HO HO	

Serial	Nο	·10	156	6201
SCITAL	INU.		/ .) U	いとラコ

No.	Structure	<u>Name</u>
157	$Br \longrightarrow O$ H_3C O	2-{4-[3-(2-benzoyl-4-bromo-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
158	H_3C O H_3C O	2-{4-[3-(2-benzoyl-4-butyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid
159	H ₃ C O H ₃ C O HO Chiral	(R)- 3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-methyl-
	CI—O OH	phenyl}-propionic acid
160	F F CH ₃ OH	(R)-3-{2-methyl-4-[3-(2-phenoxy-4-trifluoromethyl-phenoxy)-butoxy]-phenyl}-propionic acid
161	Chiral Chiral Chiral CH ₃ OH OH	(R)-3-{2-methyl-4-[3-(2-phenoxy-4-trifluoromethoxy-phenoxy)-butoxy]-phenyl}-propionic acid

Serial	Nο	·10	156	6201
SCITAL	INU.		/ .) U	いとラコ

No.	Structure	<u>Name</u>
162	H ₃ C—Chiral O CH ₃ O OH	(R)-3-{2-methyl-4-[3-(4-methyl-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
163	CI—CH ₃ OH OH	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-methyl-phenylsulfanyl}-acetic acid
164	CI————————————————————————————————————	3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-propoxy]-2-methyl-phenyl}-propionic acid
165	CI—CH ₃ OH OH	(R)-3-{4-[3-(2-benzo[b]thiophen-3-yl-4-chloro-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
166	CI—OCH ₃ OH OH	(R)- 3-{4-[3-(4-chloro-2-pyridin-3-yl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
167	CI—O—O—F F OH	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-2,2-difluoro-propionic acid

Serial	No.:10/566291
--------	---------------

No.	Structure	Name
168	Chiral	%)(R)-3-{3-bromo-4-[3-
		(4-chloro-2-phenoxy-
	O Br	phenoxy)-butoxy]-
		phenyl}-propionic acid
	CH ₃	
169	Chiral	(R)-3-{4-[3-(4-chloro-2-
		phenoxy-phenoxy)-
	O H ₃ C	butoxy]-3-methyl-
		phenyl}-propionic acid
	ĈH₃ OH	
170	Chiral	(R)-{3-bromo-4-[3-(4-
		chloro-2-phenoxy-
	O Br	phenoxy)-butoxy]-
		phenyl}-acetic acid
	CH ₃ HO	
171	F Chiral	(R)-3-{4-[3-(4-bromo-2-
	,cH₃	trifluoromethoxy-
	Br O O	phenoxy)-butoxy]-2-
	CH ₃ OH	methyl-phenyl}-
	3	propionic acid
172	Chiral	(R)-{4-[3-(4-chloro-2-
		phenoxy-phenoxy)-
	O H ₃ C	butoxy]-3-methyl-
	$CI \longrightarrow O \longrightarrow $	phenyl}-acetic acid
173	Chiral	(R)-{4-[3-(4-chloro-2-
		phenoxy-phenoxy)-
		butoxy]-phenyl}-acetic
	CI	acid
	CH ₃	
	HO ~ O	

Serial	Nο	·10	156	6201
SCITAL	INU.		/ .) U	いとラコ

No.	Structure	Name
174	CI Chiral OH	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-2-trifluoromethyl-phenyl}-propionic acid
175	CI—CH ₃ CH ₃ OH	(R)-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenoxy}-acetic acid
176	CI—CH ₃ OH	(R)-3-{4-[3-(4-chloro-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
177	CI O Chiral OH	(R)-3-{2-Chloro-4-[3-(4-chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
178	CI Chiral OH	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-fluoro-phenyl}-propionic acid
179	Chiral	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid

Serial No.:10/566291	

No.	Structure	<u>Name</u>
180	CI O Chiral OH	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-chloro-phenyl}-propionic acid
181	F O Chiral OH	(R)-3-{4-[3-(2-Benzoyl- 4-ethyl-phenoxy)- butoxy]-2-fluoro- phenyl}-propionic acid
182	CI OH OH	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-phenyl}-propionic acid
183	O Chiral OH	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-phenyl}-propionic acid
184	CI O Chiral OH OH OH	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid
185	O Chiral OH Isomer 1	(R)-3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-pentyloxy]-2-methyl-phenyl}-propionic acid

Serial	No.	10/566291
Scriar	INO.	10/300231

No.	Structure	Name
186	Chiral OH	(R)-{4-[3-(3-Benzoyl-naphthalen-2-yloxy)-butoxy]-2-methyl-phenylsulfanyl}-aceticacid
187	Chiral	(R)-3-{4-[3-(3-Benzoyl-naphthalen-2-yloxy)-butoxy]-2-methyl-phenyl}-propionic acid
188	O Chiral OH	(R)-3-{4-[3-(4-Ethyl-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
189	O Chiral OH	(R)-3-{4-[3-(4-Isopropyl-2-phenoxy-phenoxy)-butylsulfanyl]-2-methyl-phenyl}-propionic acid
190	Cl	(R)-3-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-propyl-phenyl}-propionic acid
191	CI S OH	(R)-{4-[3-(4-Chloro-2-phenoxy-phenoxy)-butoxy]-2-ethyl-phenylsulfanyl}-acetic acid

Serial	No	.10	156	6291
SCHAL	INU.	1	/ .) ()	ハノムフィ

No.	Structure	<u>Name</u>
192	CI O Chiral	(R)-3-{4-[3-(2-Benzoyl-
	CIOH	4,5-dichloro-phenoxy)-
		butoxy]-2-methyl-
		phenyl}-propionic acid
102	O. Okind	(D) 2 (2 M d 1 4 F2 (2
193	CF ₃ OH	(R)-3-{2-Methyl-4-[3-(2-
		phenoxy-4-
		trifluoromethyl-
		phenoxy)-butylsulfanyl]-
101		phenyl}-propionic acid
194	Chiral	(R)-3-{2-Ethyl-4-[3-(4-
	ОН	ethyl-2-phenoxy-
		phenoxy)-butoxy]-
		phenyl}-propionic acid
	~	
195	Chiral	(R)-3-{2-Ethyl-4-[3-(2-
	CF ₃ OH	phenoxy-4-
		trifluoromethyl-
		phenoxy)-butoxy]-
	~	phenyl}-propionic acid
196	Chiral	(R)-3-{4-[3-(2-Benzoyl-
	OH OH	4-ethyl-phenoxy)-
		butoxy]-2-ethyl-phenyl}-
		propionic acid
197	Chiral	(R)-3-{2-Ethyl-4-[1-
	CF ₃ OH	methyl-3-(2-phenoxy-4-
		trifluoromethyl-
		phenoxy)-propoxy]-
		phenyl}-propionic acid

Serial	Nο	.10	156	6291
OCHAL	INU.		/ . J.	ハラノ・フェ

No.	Structure	<u>Name</u>
198	-F c O Chiral	(R)-3-{2-Methyl-4-[1-
	F OH OH	methyl-3-(2-phenoxy-4-
	Foots	trifluoromethoxy-
		phenoxy)-
	~	propylsulfanyl]-phenyl}-
		propionic acid
199	→ O Chiral	(S)-3-{4-[3-(4-Chloro-2-
	CI OH	phenoxy-phenoxy)-
		butoxy]-2-ethyl-phenyl}-
	r o	propionic acid
200	> 0	3-{4-[3-(4-Chloro-2-
	CI	phenoxy-phenoxy)-
		propoxy]-2-ethyl-
	r o o o o o o o o o o o o o o o o o o o	phenyl}-propionic acid
201	→ O Chiral	(R)-3-{4-[3-(2,4-
	□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	Diphenoxy-phenoxy)-
		butoxy]-2-ethyl-phenyl}-
	°	propionic acid
202	Cl	2-{4-[4-(4-Chloro-2-
	ОН	phenoxy-phenyl)-3-
	, 10. 0. 0. 0. 0.	methyl-butoxy]-2-
	Cis - Isomer 2	methyl-phenyl}-
		cyclopropanecarboxylic
		acid
203		(R, S)-2-{4-[3-(4-Ethyl-
		2-phenylsulfanyl-
	H ₃ C OH	phenoxy)-butoxy]-
	CH ₃	phenoxy}-2-methyl-
		propionic acid

Serial	N_{Ω}	·10	150	6620	1
Scriai	INO.	/	ω	リロムタ .	ı

No.	Structure	<u>Name</u>
204	H ₃ C CH ₃ CH ₃ OH	2-{4-[3-(R,S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]- 2-methyl-phenylsulfanyl}-2- methyl-propionic acid (enamtiomer pair 1)
205	F F CH ₃ OH CH ₃	(R, S)-2-{4-[3-(2- Cyclopropylmethyl-4- trifluoromethyl- phenoxy)-butoxy]- phenoxy}-2-methyl- propionic acid
206	H ₃ C OH CH ₃ CH ₃ OH	(R, S)-2-Methyl-2-{4-[3- (2-methyl-3-phenyl-7- propyl- benzofuran-6-yloxy)- butoxy]-phenoxy}- propionic acid
207	CH ₃ CH ₃ CH ₃ CH ₃ CH ₃	(R, S)-2-Methyl-2-{4-[3- (4-methyl-3-phenyl-7- propyl- benzofuran-6-yloxy)- butoxy]-phenoxy}- propionic acid

Serial	N_{Ω}	·10	151	56201	١
SCHai	INO.		/ 21	ひひ ムタコ	L

No.	Structure	<u>Name</u>
208	CH ₃ H ₃ C OH CH ₃	(R, S)-2-{4-[3-(2- Cyclopropylmethyl-4- trifluoromethyl- phenoxy)-butoxy]-2- methyl-phenoxy}-2- methyl-propionic acid
209	F F CH ₃ OH	(R, S)-3-{4-[3-(2- Cyclopropylmethyl-4- trifluoromethyl- phenoxy)-butoxy]-2- methyl-phenyl}- propionic acid
210	H ₃ C CH ₃ OH	3-{R-4-[3-(R, S-2- Benzenesulfinyl-4-ethyl- phenoxy)-butoxy]- 2-methyl-phenyl}- propionic acid
211	H ₃ C CH ₃ OH	3-{4-[3-(4-Ethyl-2- phenylsulfanyl- phenoxy)-butoxy]- 2-methyl-phenyl}- propionic acid isomer 2
212	H ₃ C CH ₃ H ₃ C OH	(R, S)-2-{4-[3-(4-Ethyl-2-phenylsulfanyl-phenoxy)-butoxy]-phenoxy}-2-methyl-propionic acid

No.	Structure	<u>Name</u>
213	H ₃ C CH ₃ OH	(R, S)-3-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
214	H ₃ C CH ₃ H ₃ C OH CH ₃	(R, S)-2-{4-[3-(R, S-2-Benzenesulfinyl-4-ethyl-phenoxy) -butoxy]-2-methyl-phenoxy}-2-methyl-propionic acid
215	H ₃ C CH ₃ OH	(R, S)-3-{4-[3-(2-Benzenesulfonyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid
216	FF CH ₃ OH	3-{4-[3-(2-Benzoyl-4- trifluoromethoxy- phenoxy)-butoxy]-2- methyl-phenyl}- propionic acid

30. (Original). The compound of Claim 29, wherein the compound is

Chiral

$$CI \longrightarrow CH_3$$
 $CI \longrightarrow CH_3$ $CI \longrightarrow$

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

- 31. (Previously Presented). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1 or a pharmaceutically acceptable salt, solvate or hydrate thereof.
 - 32. (Canceled).
 - 33. (Canceled).
 - 34. (Canceled).
 - 35. (Canceled).
 - 36. (Canceled).
 - 37. (Canceled).
 - 38. (Canceled).
 - 39. (Canceled).
 - 40. (Canceled).
 - 41. (Canceled).
 - 42. (Canceled).
- 43. (Previously Presented). A method for lowering blood-glucose in a mammal in need thereof comprising the step of administering an effective amount of a compound of Claim 1.
 - 44. (Canceled).
 - 45. (Canceled).
 - 46. (Canceled).
 - 47. (Canceled).
 - 48. (Canceled).
 - 49. (Canceled)